Key Takeaways

MOTS-C is commonly framed in the wellness market as a metabolic, mitochondrial, or “exercise-mimetic” peptide, with claims around energy, insulin sensitivity, fat loss, performance, bone health, and healthy aging.
The science below supports a narrower summary: MOTS-C is an endogenous 16-amino-acid mitochondrial-derived peptide involved in metabolic-stress signaling, with the strongest evidence coming from cell and animal studies, plus limited human literature measuring endogenous MOTS-C in exercise response and biomarker contexts.
Mouse studies and mechanistic papers suggest possible roles in AMPK-related signaling, metabolic homeostasis, muscle biology, adipose biology, and bone-related pathways, but they do not prove that injected or compounded native MOTS-C improves weight loss, endurance, insulin resistance, osteoporosis, longevity, or recovery in humans.
A separate analogue, CB4211, has its own early human development record, but that evidence should not be treated as direct proof for native MOTS-C; the peptide remains investigational, not FDA-approved for any indication, and FDA has specifically flagged missing human exposure and safety information for drug products containing MOTS-C.

‍

[Benayoun et al., 2019; Lee et al., 2015; Kim et al., 2018; Reynolds et al., 2021; Ming et al., 2016; ClinicalTrials.gov, 2026; SEC, 2021; FDA, 2026].

MOTS-C: An experimental mitochondrial-derived peptide, typically described as a 16-amino-acid product of a short open reading frame within mitochondrial 12S rRNA — canonical human sequence MRWQEMGYIFYPRKLR.

Overview

MOTS-C is an endogenous mitochondrial-derived 16-amino-acid microprotein encoded in the 12S rRNA/MT-RNR1 region of mitochondrial DNA. However, the compound that appears in clinics, research catalogs, and compounding discussions is the synthetic exogenous version. Evidence from optimized analog programs such as CB4211 should not be presented as if it were direct human efficacy evidence for native MOTS-C. [Lee et al., 2015; Benayoun et al., 2019; ADDF, 2025; CohBar, 2018]

What it is

MOTS-C, short for mitochondrial open reading frame of the 12S rRNA type-c, is a 16-amino-acid peptide encoded by a 51-bp short open reading frame within the mitochondrial 12S rRNA/MT-RNR1 region. Secondary and technical sources describe the human native sequence as MRWQEMGYIFYPRKLR (chemical formula: C101H152N28O22S2; molecular weight of 2174.6 Da) for the unmodified peptide. The most important molecular distinction here is that endogenous MOTS-C is the naturally produced signaling microprotein, whereas exogenous "MOTS-C" in research and wellness settings is a synthetic peptide intended to match that endogenous sequence. [Benayoun et al., 2019; ADDF, 2025; NCATS Inxight Drugs, 2025]

MOTS-C free base and MOTS-C acetate are separate bulk drug substances used in compounding and sourcing contexts, and neither designation is evidence that either form has an approved medical use. Separate from both of those is CB4211, which its sponsor described as a "novel and improved analog of MOTS-c." Native MOTS-C, salt/formulation labels, and analog programs should not be collapsed into one evidence bucket. [FDA, 2026; CohBar, 2018]

Native MOTS-C claims must stand on native MOTS-C evidence. A human biomarker paper about endogenous circulating MOTS-C does not prove therapeutic benefit from injected synthetic MOTS-C. A Phase 1 program on CB4211 does not establish safety or efficacy for native MOTS-C. And a mouse or cell-system effect should be described as exactly that — not converted into a patient-facing clinical outcome. [Qin et al., 2018; Reynolds et al., 2021; ClinicalTrials.gov, 2019; USADA, 2023]

How it's proposed to work

The best-supported mechanistic backbone comes from the discovery and early follow-up literature. Lee and colleagues reported that MOTS-C alters cellular metabolism by inhibiting the folate cycle and de novo purine biosynthesis. This promotes accumulation of AICAR, and activates AMPK. The clearest metabolic effects are observed in skeletal muscle in mouse models. Reviews of the same literature confirm that the folate–AICAR–AMPK axis is the central first-line mechanism, while emphasizing that this is still a mechanistic map and not proof of human therapeutic effect. [Lee et al., 2015; Lee, 2016; Wan et al., 2023; Kong et al., 2023]

Kim and colleagues added the second major layer in 2018 by showing that MOTS-C can translocate to the nucleus in an AMPK-dependent manner under metabolic stress and regulate adaptive nuclear gene expression. Subsequent reviews characterize this as a form of mitochondrial-to-nuclear stress signaling and connect it to antioxidant-response and stress-adaptation programs, but those downstream transcriptional maps are still preclinical. [Kim et al., 2018; Benayoun et al., 2019; Mohtashami et al., 2022]

Later preclinical work has refined, but not fully settled, the target picture. For example, Bhullar and colleagues linked MOTS-C-induced GLUT4 translocation in skeletal muscle cells to mitofusin-2, while Kumagai and colleagues reported that MOTS-C can directly bind and activate casein kinase 2, again in a preclinical skeletal-muscle context. [Bhullar et al., 2021; Kumagai et al., 2024]

The tissue emphasis is likewise important. The literature repeatedly points to skeletal muscle as the dominant metabolic-response tissue in the native discovery program, while later work also describes activity in adipose tissue, bone-related cell systems, vascular endothelium, and pancreatic islet models. A bone-loss mouse model, an endothelial-association study, and an exercise-induced skeletal-muscle signal are not interchangeable proof. [Lee et al., 2015; Qin et al., 2018; Ming et al., 2016; Lu et al., 2019; Kong et al., 2025]

Common forms in circulation

In the scientific literature, native MOTS-C generally appears as a synthetic unmodified peptide administered experimentally by systemic injection in rodents or cell systems. FDA materials identify MOTS-C free base and acetate as the forms evaluated for the 503A Bulks List. [Lee et al., 2015; Reynolds et al., 2021; FDA, 2026]

In public-facing clinic and peptide-market discourse, MOTS-C is most commonly described as a lyophilized, reconstituted injectable peptide delivered subcutaneously. That description reflects how the molecule is being marketed or protocolized in the wellness space, but is not a validated FDA-approved route or dose. [Innerbody, 2026]

Names and aliases

The main scientific names to track are MOTS-C, MOTS-c, and mitochondrial open reading frame of the 12S rRNA type-c. The human gene-region reference is often given as MT-RNR1 or the 12S rRNA region of mtDNA. Current FDA agenda language also uses the formulation variants MOTS-C (free base) and MOTS-C acetate. [Benayoun et al., 2019; FDA, 2026]

The most important warning is between native MOTS-C and MOTS-C-derived analogs, especially CB4211. The second-most important is between endogenous physiology and exogenous clinic use. The third is between mechanistic language such as "exercise mimetic" and clinically demonstrated patient benefit. [Reynolds et al., 2021; CohBar, 2018; USADA, 2023]

Regulatory status

Native MOTS-C has no FDA-approved indication. Compounded drugs are not FDA-approved, meaning FDA has not verified their safety, effectiveness, or quality before marketing. FDA's page on substances that may present significant safety risks includes MOTS-C under "bulk drug substances nominated but withdrawn," and states that compounded MOTS-C may pose significant risk for immunogenicity for certain routes of administration and may present complexities regarding peptide-related impurities and API characterization; FDA further states that it has not identified any human exposure data on compounded MOTS-C products administered by any route and therefore lacks important information regarding whether MOTS-C would cause harm if administered to humans. [FDA, 2025; FDA, 2026]

On July 23, 2026, the Pharmacy Compounding Advisory Committee met to reconsider MOTS-C free base and acetate for potential inclusion on the 503A Bulks List, evaluating the substances for obesity and osteoporosis. FDA staff had recommended that neither be added, concluding that the substances were not well characterized, that their use in compounding was unknown, that no human clinical studies or exposure data had been identified, and that clinical and nonclinical safety information was insufficient. The committee nonetheless voted 7-5, with two abstentions, to recommend adding MOTS-C free base and acetate to the 503A Bulks List. [FDA MOTS-c briefing document; FDA 7/23-24/26 PCAC; Reuters 7/23/26]

The recommendation is advisory only: FDA has not added MOTS-C to the 503A Bulks List, and the vote does not itself authorize compounding, establish safety or efficacy, or constitute FDA approval. As with several other peptides considered that week, the committee's vote ran counter to FDA staff's own recommendation. [FDA MOTS-c briefing document; FDA 7/23-24/26 PCAC]

Evidence base

Evidence tier	What qualifies	What it does not justify
Clinical trial	Prospective interventional human study of the same molecule or a clearly labeled analogue, in a defined population, with stated outcomes.	Translating analogue results into native-MOTS-C claims without qualification; claiming efficacy from safety-only or exploratory studies.
Animal model	In vivo rodent or other animal studies using exogenous MOTS-C or a labeled analogue.	Human treatment claims, dose assumptions, safety assumptions, or guaranteed outcomes.
Mechanistic hypothesis	Cell, tissue, pathway, signaling, biomarker, or translocation data.	Patient-facing promises about symptoms, disease outcomes, body composition, energy, or longevity.
Anecdotal	Clinic copy, influencer claims, patient stories, user reports, or community observations.	Any clinical efficacy or safety assertion.

Purported benefits, by evidence

Purported benefit	Tagged evidence strength	What the evidence supports	What it does not support
Native MOTS-C improves insulin sensitivity in humans	Clinical trial: unspecified for native MOTS-C; analogue-only human evidence	No published randomized efficacy trial of native therapeutic MOTS-C was identified. FDA's 2026 review did not identify clinical studies administering MOTS-C-related bulk drug substances to humans or human exposure data for any route. Human interventional evidence found is for CB4211, a MOTS-C analogue, not native MOTS-C.	"Clinically proven in humans," "reverses insulin resistance," "treats prediabetes/diabetes," or any unqualified efficacy promise for native MOTS-C. [FDA, 2026; ClinicalTrials.gov, 2026; SEC, 2021]
Improves insulin sensitivity / glucose handling	Animal model	Mouse studies support metabolic effects, including improved insulin sensitivity and altered metabolomic pathways. Human studies mainly show endogenous-level associations or acute physiological responses rather than treatment efficacy.	A patient-facing claim that injected native MOTS-C is proven to improve glucose control in people. [Lee et al., 2015; Kim et al., 2019; Cataldo et al., 2018]
Weight loss / fat loss / visceral-fat reduction	Animal model for native MOTS-C; analogue exploratory human signal	Mouse papers support prevention or attenuation of diet-induced or ovariectomy-associated metabolic dysfunction and adiposity. CB4211 showed only a trend toward lower body weight in a short sponsor-reported study, while liver-fat decreased similarly in placebo during confinement on a standardized diet.	"Weight-loss peptide," "rapid fat burner," "visceral-fat reducer," or "proven body-composition therapy" in humans. [Lee et al., 2015; Lu et al., 2019; SEC, 2021]
Exercise mimetic / endurance / performance support	Animal model for exogenous use; human observational for endogenous response	Reynolds et al. showed improved physical performance and later-life healthspan metrics in mice, and the paper also reported that exercise increases endogenous MOTS-C expression in humans.	"Exercise in a vial," "improves performance in humans," or "clinically proven endurance enhancer." Also unsuitable for athlete-targeted promotion given anti-doping status. [Reynolds et al., 2021; USADA, 2023; WADA, 2025]
Bone health / osteoporosis support	Animal model and mechanistic hypothesis	Bone-related evidence comes from ovariectomy and osteoblast/BMSC work. That supports scientific plausibility and preclinical exploration, not clinical osteoporosis treatment claims.	"Treats osteoporosis," "prevents fractures," or "proven bone-restorative peptide" in people. [Ming et al., 2016; Che et al., 2019]
Healthy aging / longevity / healthspan	Animal model	Late-life intermittent dosing improved physical-capacity and healthspan-related metrics in mice.	Human longevity claims, anti-aging guarantees, age-reversal claims, or "supports healthy aging" stated as a proven clinical outcome. [Reynolds et al., 2021]

Key literature

Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. Core metabolic homeostasis story for MOTS-C; insulin sensitivity and obesity signals in mice.

Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018;28(3):516-524.e7. Strong mechanistic basis for "metabolic-stress signaling" and nuclear-translocation.

Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. Best source for "exercise-induced peptide" language and late-life mouse performance data.

D'Souza RF, Woodhead JST, Hedges CP, et al. Increased expression of the mitochondrial-derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. Aging (Albany NY). 2020;12:5244-5258. Supports endogenous aging-muscle association language.

Ming W, Lu G, Xin S, et al. Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation. Biochem Biophys Res Commun. 2016;476(4):412-419. Preclinical bone-related evidence.

References

Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454.
Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018;28(3):516-524.e7.
Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Updated April 22, 2026.
U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee — FDA Briefing Document for MOTS-c-Related Bulk Drug Substances.
Reuters. FDA advisers back first four of seven unapproved peptides under review for looser rules. July 23, 2026; updated July 24, 2026.
ClinicalTrials.gov. A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease. NCT03998514.
U.S. Anti-Doping Agency. What is the MOTS-c peptide? Published 2023.
World Anti-Doping Agency. 2026 Prohibited List and explanatory materials identifying MOTS-c as an example of an AMP-activated protein kinase activator.

MOTS-C